Literature DB >> 19948089

Statins in the prevention of heart failure after myocardial infarction.

Helene Glassberg1.   

Abstract

Statin therapy has demonstrated clear reductions in the risk of death and recurrent cardiac events in patients with acute coronary syndrome (ACS) and coronary artery disease. Heart failure after myocardial infarction (MI) is associated with increased in-hospital mortality and worse long-term prognosis. Some controversy exists about the effects of statin therapy on heart failure, although the favorable effects of statin therapy likely reduce the risk of heart failure development after MI and ACS. This article reviews data on statin therapy and the incidence of heart failure after MI, discussing mechanisms, safety, and outcomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19948089     DOI: 10.1007/s11897-009-0030-8

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  39 in total

1.  2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation.

Authors:  Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2009-04-14       Impact factor: 24.094

2.  Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure.

Authors:  Bojan Vrtovec; Renata Okrajsek; Alenka Golicnik; Mateja Ferjan; Vito Starc; Branislav Radovancevic
Journal:  J Card Fail       Date:  2005-12       Impact factor: 5.712

3.  Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report.

Authors:  Hidekatsu Fukuta; David C Sane; Steffen Brucks; William C Little
Journal:  Circulation       Date:  2005-07-11       Impact factor: 29.690

4.  The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle.

Authors:  R Laaksonen; K Jokelainen; J Laakso; T Sahi; M Harkonen; M J Tikkanen; J J Himberg
Journal:  Am J Cardiol       Date:  1996-04-15       Impact factor: 2.778

5.  Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis.

Authors:  J D Luo; W W Zhang; G P Zhang; J X Guan; X Chen
Journal:  Clin Exp Pharmacol Physiol       Date:  1999-11       Impact factor: 2.557

6.  Statins and chronic heart failure: do we need a large-scale outcome trial?

Authors:  Henry Krum; John J McMurray
Journal:  J Am Coll Cardiol       Date:  2002-05-15       Impact factor: 24.094

Review 7.  The endotoxin-lipoprotein hypothesis.

Authors:  M Rauchhaus; A J Coats; S D Anker
Journal:  Lancet       Date:  2000-09-09       Impact factor: 79.321

8.  Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure.

Authors:  Tamara B Horwich; W Robb MacLellan; Gregg C Fonarow
Journal:  J Am Coll Cardiol       Date:  2004-02-18       Impact factor: 24.094

9.  Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy.

Authors:  Koichi Node; Masashi Fujita; Masafumi Kitakaze; Masatsugu Hori; James K Liao
Journal:  Circulation       Date:  2003-07-28       Impact factor: 29.690

10.  Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.

Authors:  Timo E Strandberg; Ingar Holme; Ole Faergeman; John J P Kastelein; Christina Lindahl; Mogens Lytken Larsen; Anders G Olsson; Terje R Pedersen; Matti J Tikkanen
Journal:  Am J Cardiol       Date:  2009-03-25       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.